Aclaris Therapeutics (ACRS) Accounts Payables (2017 - 2025)
Historic Accounts Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $9.2 million.
- Aclaris Therapeutics' Accounts Payables rose 1990.34% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 1990.34%. This contributed to the annual value of $4.7 million for FY2024, which is 4717.28% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Accounts Payables is $9.2 million, which was up 1990.34% from $8.8 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Accounts Payables registered a high of $11.4 million during Q2 2023, and its lowest value of $4.2 million during Q2 2021.
- In the last 5 years, Aclaris Therapeutics' Accounts Payables had a median value of $8.1 million in 2022 and averaged $8.1 million.
- Per our database at Business Quant, Aclaris Therapeutics' Accounts Payables surged by 10033.32% in 2023 and then plummeted by 4717.28% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Accounts Payables stood at $10.0 million in 2021, then increased by 3.67% to $10.4 million in 2022, then fell by 14.23% to $8.9 million in 2023, then tumbled by 47.17% to $4.7 million in 2024, then skyrocketed by 95.88% to $9.2 million in 2025.
- Its Accounts Payables stands at $9.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $6.4 million for Q1 2025.